259 related articles for article (PubMed ID: 32413699)
1. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
Bou Khalil R
Med Hypotheses; 2020 Sep; 142():109798. PubMed ID: 32413699
[No Abstract] [Full Text] [Related]
2. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
3. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
4. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
5. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
6. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Husain A; Byrareddy SN
Chem Biol Interact; 2020 Nov; 331():109282. PubMed ID: 33031791
[TBL] [Abstract][Full Text] [Related]
7. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
DiNicolantonio JJ; Barroso J; McCarty M
Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
[No Abstract] [Full Text] [Related]
8. A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.
Ren YR; Golding A; Sorbello A; Ji P; Chen J; Saluja B; Witzmann K; Arya V; Reynolds KS; Choi SY; Nikolov NP; Sahajwalla C
J Clin Pharmacol; 2020 Aug; 60(8):954-975. PubMed ID: 32469437
[TBL] [Abstract][Full Text] [Related]
9. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
10. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
[No Abstract] [Full Text] [Related]
11. Hydroxychloroquine in Covid-19: Does the end justify the means?
Yakoub-Agha I
Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
[No Abstract] [Full Text] [Related]
12. Surviving COVID-19: A disease tolerance perspective.
Ayres JS
Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
[No Abstract] [Full Text] [Related]
13. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
Regidor PA
Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
[No Abstract] [Full Text] [Related]
14. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.
Rofeal M; El-Malek FA
Med Hypotheses; 2020 Oct; 143():109904. PubMed ID: 32502901
[TBL] [Abstract][Full Text] [Related]
15. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19.
Sodhi M; Etminan M
Pharmacotherapy; 2020 May; 40(5):487-488. PubMed ID: 32267566
[No Abstract] [Full Text] [Related]
17. A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection.
Mayor-Ibarguren A; Busca-Arenzana C; Robles-Marhuenda Á
Front Immunol; 2020; 11():1736. PubMed ID: 32754165
[No Abstract] [Full Text] [Related]
18. COVID-19 in a Kidney Transplant Patient.
Wang J; Li X; Cao G; Wu X; Wang Z; Yan T
Eur Urol; 2020 Jun; 77(6):769-770. PubMed ID: 32273181
[No Abstract] [Full Text] [Related]
19. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
20. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
